Skip to main content

Table 3 Characteristics of study participants

From: I don’t want to think about it: a qualitative study of children (6–18 years) with rheumatic diseases and parents’ experiences with regular needle injections at home

Participants Characteristics
Individual interviews
 Children:
  Gender 5 females, 2 males
  Age at interview 6–16 years (mean 12 years, 4 ≤ 12 years and 3 > 12 years)
  Disease duration 4–6 months (mean 5.6 months)a
  Diagnosis Oligo JIA (2), Poly JIA (2), Enthesitis-related JIA (1), Juvenile dermatomyositis (1), Behcets disease (1)
  Medications received Methotrexate (oral or s.c.) in combination with etanercept (Enbrel/Benepali) s.c (3) or tocilizumab (RoActemra) s.c. (1), etanercept (Enbrel) s.c. (1), methotrexate (Metex) s.c. (1) and adalimumab (Humira) s.c (1)
 Parents (of the same children):
  Gender 7 females, 1 male
Focus groups
 Children (in two groups):
  Gender 6 females, 3 males
  Age at time of focus group 11–13 years (mean 12 years) in the first group and 14–17 years (mean 15.8 years) in the second group.
  Disease duration 6 months – 15 years (mean 8.1 years)
  Diagnosis Unspecified JIA (5), Oligo JIA (1), Poly JIA (2), Systemic JIA (1) (self-reported)
  Medications received Methotrexate (oral or s.c.) in combination with etanercept (Enbrel/Benepali) s.c (3) or tocilizumab (RoActemra) s.c. (1), methotrexate (Metex) s.c. (3), tocilizumab (RoActemra) i.v. (1) (earlier s.c. medication) and methotrexate oral (1) (earlier s.c. medication)b
 Parents (in two groups):
  Gender 5 females, 3 males
  Disease duration (child) 1–15 years (mean 7.2 years)
  Diagnosis (child) Unspecified JIA (5), Poly JIA (2), Systemic JIA (1) (self-reported)
  Medications received (child) Methotrexate (oral in combination with etanercept (Enbrel) s.c (2) or adalimumab. (Humira) s.c (1), methotrexate (Metex) s.c. (2), and methotrexate oral (2)
  1. Number of participants: (n), Abbreviations: JIA Juvenile Idiopathic Arthritis, s.c. subcutaneous
  2. aOne child was diagnosed 10 years ago and had previous experience with s.c. injections, but after several years without s.c. injections she was readmitted 6 month earlier and needed updated education
  3. bDue to severe side effects of injections or severe needle–fear converted from subcutaneous to oral administrations